Annual CFF
$296.64 M
-$44.06 M-12.93%
December 31, 2023
Summary
- As of February 7, 2025, SWTX annual cash flow from financing activities is $296.64 million, with the most recent change of -$44.06 million (-12.93%) on December 31, 2023.
- During the last 3 years, SWTX annual CFF has risen by +$26.15 million (+9.67%).
- SWTX annual CFF is now -12.93% below its all-time high of $340.70 million, reached on December 31, 2022.
Performance
SWTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$1.29 M
-$2.08 M-61.70%
September 30, 2024
Summary
- As of February 7, 2025, SWTX quarterly cash flow from financing activities is $1.29 million, with the most recent change of -$2.08 million (-61.70%) on September 30, 2024.
- Over the past year, SWTX quarterly CFF has dropped by -$2.08 million (-61.70%).
- SWTX quarterly CFF is now -99.62% below its all-time high of $340.23 million, reached on September 30, 2022.
Performance
SWTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$303.18 M
+$1.53 M+0.51%
September 30, 2024
Summary
- As of February 7, 2025, SWTX TTM cash flow from financing activities is $303.18 million, with the most recent change of +$1.53 million (+0.51%) on September 30, 2024.
- Over the past year, SWTX TTM CFF has increased by +$1.53 million (+0.51%).
- SWTX TTM CFF is now -11.01% below its all-time high of $340.70 million, reached on December 31, 2022.
Performance
SWTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SWTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -12.9% | -61.7% | +0.5% |
| 3 y3 years | +9.7% | -61.7% | +0.5% |
| 5 y5 years | +488.9% | -61.7% | +0.5% |
SWTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -12.9% | >+9999.0% | -99.6% | +169.9% | -11.0% | >+9999.0% |
| 5 y | 5-year | -12.9% | >+9999.0% | -99.6% | +169.9% | -11.0% | >+9999.0% |
| alltime | all time | -12.9% | >+9999.0% | -99.6% | +169.9% | -11.0% | >+9999.0% |
SpringWorks Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $1.29 M(-61.7%) | $303.18 M(+0.5%) |
| Jun 2024 | - | $3.37 M(-710.7%) | $301.65 M(+1.2%) |
| Mar 2024 | - | -$552.00 K(-100.2%) | $297.94 M(+0.4%) |
| Dec 2023 | $296.64 M(-12.9%) | $299.07 M(<-9900.0%) | $296.64 M(<-9900.0%) |
| Sep 2023 | - | -$242.00 K(-29.2%) | -$2.13 M(-100.6%) |
| Jun 2023 | - | -$342.00 K(-81.5%) | $338.34 M(-0.1%) |
| Mar 2023 | - | -$1.85 M(-720.1%) | $338.59 M(-0.6%) |
| Dec 2022 | $340.70 M(>+9900.0%) | $298.00 K(-99.9%) | $340.70 M(+0.0%) |
| Sep 2022 | - | $340.23 M(<-9900.0%) | $340.65 M(>+9900.0%) |
| Jun 2022 | - | -$88.00 K(-133.7%) | $842.00 K(-20.5%) |
| Mar 2022 | - | $261.00 K(+7.0%) | $1.06 M(-8.5%) |
| Dec 2021 | $1.16 M | $244.00 K(-42.6%) | $1.16 M(-99.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2021 | - | $425.00 K(+229.5%) | $270.89 M(-0.0%) |
| Jun 2021 | - | $129.00 K(-64.1%) | $270.89 M(+0.0%) |
| Mar 2021 | - | $359.00 K(-99.9%) | $270.84 M(+0.1%) |
| Dec 2020 | $270.49 M(-18.9%) | $269.97 M(>+9900.0%) | $270.49 M(>+9900.0%) |
| Sep 2020 | - | $428.00 K(+448.7%) | $532.00 K(-99.7%) |
| Jun 2020 | - | $78.00 K(+1200.0%) | $169.84 M(+0.0%) |
| Mar 2020 | - | $6000.00(-70.0%) | $169.76 M(-49.1%) |
| Dec 2019 | $333.71 M(+562.4%) | $20.00 K(-100.0%) | $333.71 M(+0.0%) |
| Sep 2019 | - | $169.73 M(>+9900.0%) | $333.69 M(+103.5%) |
| Jun 2019 | - | $0.00(-100.0%) | $163.96 M(0.0%) |
| Mar 2019 | - | $163.96 M | $163.96 M |
| Dec 2018 | $50.38 M | - | - |
FAQ
- What is SpringWorks Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics annual CFF year-on-year change?
- What is SpringWorks Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics quarterly CFF year-on-year change?
- What is SpringWorks Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for SpringWorks Therapeutics?
- What is SpringWorks Therapeutics TTM CFF year-on-year change?
What is SpringWorks Therapeutics annual cash flow from financing activities?
The current annual CFF of SWTX is $296.64 M
What is the all time high annual CFF for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high annual cash flow from financing activities is $340.70 M
What is SpringWorks Therapeutics annual CFF year-on-year change?
Over the past year, SWTX annual cash flow from financing activities has changed by -$44.06 M (-12.93%)
What is SpringWorks Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SWTX is $1.29 M
What is the all time high quarterly CFF for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high quarterly cash flow from financing activities is $340.23 M
What is SpringWorks Therapeutics quarterly CFF year-on-year change?
Over the past year, SWTX quarterly cash flow from financing activities has changed by -$2.08 M (-61.70%)
What is SpringWorks Therapeutics TTM cash flow from financing activities?
The current TTM CFF of SWTX is $303.18 M
What is the all time high TTM CFF for SpringWorks Therapeutics?
SpringWorks Therapeutics all-time high TTM cash flow from financing activities is $340.70 M
What is SpringWorks Therapeutics TTM CFF year-on-year change?
Over the past year, SWTX TTM cash flow from financing activities has changed by +$1.53 M (+0.51%)